MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

Anti-Prostate Cancer Compound Library

MCE 站：Anti-Prostate Cancer Compound Library

Cancer is one of the leading causes of mortality amongst world’s population, in which prostate cancer (PCa) is one of the most encountered malignancies among men. Several molecular mechanisms are involved in prostate cancer development ａnd progression. These include common survival factors in prostate cancer (IGF-1), growth factors (TGF-α, EGF), Wnt, Hedgehog, NF-κB, ａnd mTOR ａnd other signaling pathways. These provide potential therapeutic target in prostate cancer treatment. MCE offers a unique collection of 1836 compounds with identified ａnd potential anti-prostate cancer activity. MCE Anti-Prostate Cancer Compound Library is a useful tool for anti-prostate cancer drugs screening ａnd other related research.

Description & Advantages:

   A unique collection of 1836 compounds for high throughput screening (HTS) ａnd high content screening (HCS).

   A useful tool for the discovery of anti-prostate cancer drugs.

   Target diverse, medicinally active ａnd cell permeable.

   Bioactivity ａnd safety confirmed by preclinical research ａnd clinical trials. Some have been approved by FDA.

   More detailed compound information with structure, IC50, ａnd other chemical & biological data.

   High purity ａnd quality validated by NMR ａnd LC/MS.

品牌介绍:
•   MCE (MedChemExpress) 拥有数百种全球独家化合物，我们致力于为全球科研客户提供*新*全的高品质小分子活性化合物；
•   10,000 多种高选择性抑制剂、激动剂涉及各热门信号通路及疾病领域；
•   设有专业的实验中心和严格的质控、验证体系；
•   提供 LC/MS、NMR、HPLC、手性分析、元素分析等各项质检报告，确保产品的高纯度、高品质；
•   产品的生物活性多经各国客户实验验证；
•   Nature, Cell, Science 等多种期刊及制药收录了MCE客户的科研成果；
•   专业团队跟踪*新的制药及生命科学研究进展，为您提供全球*新的活性化合物；
•   与世界各大制药公司及知名科研机构建立了长期的合作。